AstraZeneca was Upgraded to a Hold Rating at Credit Suisse

By Jason Carr

Credit Suisse analyst Rebekah Harper upgraded AstraZeneca (NYSE: AZN) to Hold today. The company’s shares closed last Friday at $34, close to its 52-week high of $35.04.

According to TipRanks.com, Harper is ranked #3473 out of 4561 analysts.

AstraZeneca has an analyst consensus of Moderate Buy.

AstraZeneca’s market cap is currently $86.09B and has a P/E ratio of 27.56. The company has a book value ratio of 6.6214.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 0156, medi 573, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on April 6, 1999 and is headquartered in London, the United Kingdom.